A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina

  • Bladder Cancer
Trial Status:

Completed

This trial runs in
Cities
  • Buenos Aires
Trial Identifier:

NCT03330886 ML39853

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      The main purpose is to study the safety and effectiveness of atezolizumab in patients with locally advanced or metastatic urothelial carcinoma whose disease has worsened during or following platinum-containing chemotherapy, or within 12 months of receiving platinum-containing chemotherapy, either before (neoadjuvant) or after (adjuvant) surgical treatment in common clinical practice settings in Argentina.

      Hoffmann-La Roche Sponsor
      NCT03330886 , ML39853 Trial Identifier
      Atezolizumab Treatments
      Urothelial Carcinoma Condition
      Official Title

      An Observational Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina

      Eligibility Criteria

      All Gender
      No Healthy Volunteers
      Inclusion Criteria
      • Signed an informed consent form submitted to the Administración Nacional de Medicamentos Alimentos y Tecnología Médica (ANMAT)
      • Histologically or cytologically documented locally advanced or metastatic urothelial carcinoma (including renal pelvis, ureters, urinary bladder, and urethra).
      • Have received at least one dose of atezolizumab as per local label and clinical practice.
      Exclusion Criteria
      • Contraindicated atezolizumab therapy

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now